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Unusual or unexpected effect of treatment
Icosapent ethyl, a form of eicosapentaenoic acid with anti-inflammatory activity, has been approved as an adjunctive treatment with statins in patients with hypertriglyceridemia. Icosapent ethyl is currently undergoing
clinical trials to determine its anti-inflammatory effects in patients with coronavirus disease 2019 (COVID-19).
This report describes 3 intensive care unit (ICU) patients with moderate to severe COVID-19 pneumonia treated with icosapent ethyl as part of their supportive care who had favorable outcomes.
Case 1 was a 75-year-old man with a past medical history of hyperlipidemia, hypertension, type 2 diabetes
mellitus, obesity, and benign prostatic hyperplasia. Case 2 was a 23-year old man with a past medical history of type 2 diabetes mellitus and obesity. Case 3 was a 24-year old man with a history of autism. All cases of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were confirmed from a nasopharyngeal swab using the Becton Dickinson nasopharyngeal reverse-transcription polymerase chain reaction. All patients in these cases were treated with a course of 2 g of icosapent ethyl twice a day by nasogastric tube.
This report of 3 cases describes the use of icosapent ethyl as a component of supportive treatments in ICU patients with moderate to severe COVID-19 pneumonia. However, as of yet there are no evidence-based treatments for SARS-CoV-2 infection from controlled clinical trials. The outcomes of ongoing clinical trials are awaited to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2 infection
and which patients might benefit from the use of this adjunctive treatment.
COVID-19 • Eicosapentaenoic Acid • Inflammation
https://www.amjcaserep.com/abstract/index/idArt/928422

2310  

~ 3   ffl:L5   -

This work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

e928422-1

21

Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)]
[Web of Science by Clarivate]

Suh W. et al.:
Icosapent ethyl for COVID-19 pneumonia
© Am J Case Rep, 2020; 21: e928422

Background
The new strain of coronavirus, labeled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is at the heart of
an ever-growing coronavirus disease 2019 (COVID-19) pandemic. In addition to the fact that more than 14 million confirmed cases have been reported, the actual burden of the
virus has been shown to be underestimated; of the numerous confirmed cases, there is a substantially greater amount
of people that have actually been exposed or infected by the
virus [1]. In recent studies, the actual immunopathogenesis
and development of severe lung and occasional systemic disease after infection have been shown to closely follow the
immune response. Specifically, research shows that coronavirus expresses surface proteins that activate the NLRP3 inflammasome, subsequently activating caspases, interleukins
(ILs), and causing the release of proinflammatory cytokines,
thus inducing pyroptosis, a highly inflammatory mechanism
of cell death when compared with the usual neat and orderly
process of apoptosis [2,3]. Thus, the respiratory sequelae morbidity commonly associated with SARS-CoV-2 infection are not
solely caused by the viral infection itself, but also by an overactivated inflammatory host immune response, marked by an
overall increase in inflammatory markers [4,5]. By that logic,
anti-inflammatory therapy may be a driving point in combating SARS-CoV2-related disease.
Indeed, such therapy involving corticosteroids and other immunosuppressants has been proposed, and clinical trials are well
underway [4,5]. One such ongoing clinical trial (NCT04412018)
(with an estimated completion date of December 2020) addresses the effects of icosapent ethyl on inflammatory biomarkers
in individuals with COVID-19 by looking at outcome measures
such as changes to high-sensitivity C-reactive protein (hs-CRP)
and the neutrophil-lymphocyte ratio [6]. Currently, icosapent
ethyl, a form of eicosapentaenoic acid, is indicated for the treatment of hypertriglyceridemia in patients at risk for ischemic
heart disease and as an adjunctive treatment with maximally tolerated doses of statin therapy [7,8]. Regulatory approval for adjunctive treatment of hypertriglyceridemia has been
supported by the findings from the ANCHOR (NCT01047501)
and the MARINE (NCT01047683) trials, showing a reduction
in inflammatory markers in treated patients [9–11]. Apart
from treatment for hypertriglyceridemia, it has been shown to
have continued anti-inflammatory activity, as determined by
the measurement of certain biomarkers of inflammation [12].
Although there have been multiple studies performed concerning icosapent ethyl’s anti-inflammatory activity in the treatment
of hypertriglyceridemia, the mechanism of icosapent ethyl in
dealing with COVID-19-induced inflammation remains speculative. One such hypothesis looks at the potential for icosapent ethyl to suppress tumor necrosis factor (TNF)-alpha
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and IL-1beta messenger ribonucleic acid expression in alveolar macrophages from asthmatic individuals [13]. Another hypothesis examines how inappropriate neutrophil activation
can result in acute lung injury, and how Resolvin E1, a derivative of eicosapentaenoic acid, promotes neutrophil apoptosis and thus reduces lung morbidity [14]. Given that previously mentioned studies have shown lung and systemic disease
from SARS-CoV-2 infection to be cytokine and immune mediated, these are several possibilities by which icosapent ethyl
can be used to modulate the course of COVID-19. Thus, perhaps immersion pulmonary edema (IPE) shows maximum benefit in patients with severe and persistent lung inflammation.
Although icosapent ethyl is not currently approved as an antiinflammatory treatment in patients with COVID-19, a recently
reported case series did show some beneficial effects in reducing symptom severity [15]. Similarly, our case series describes
3 intensive care unit (ICU) patients with moderate to severe
COVID-19 pneumonia treated with icosapent ethyl as part of
their supportive care who had favorable outcomes with a reduction in inflammatory markers. None of the patients listed
in the following cases has been recruited to any other ongoing clinical trials.

Case Reports
The following cases of SARS-CoV-2 infection were confirmed
from a nasopharyngeal swab using the Becton Dickinson nasopharyngeal reverse-transcription polymerase chain reaction
(RT-PCR) test that has received emergency use authorization
from the U.S. Food and Drug Administration. RT-PCR testing was
performed using Clinical Laboratory Improvement Amendments
diagnostic standards according to current testing guidelines.
Per guidelines, it is important that positive PCR tests be confirmed to avoid any false positives, whereas testing of multiple specimens/multiple body sites tested be performed to
decrease the risk of false negatives and ensure proper supportive treatment of such patients [16]. All patients in these
cases were treated with 2 g of icosapent ethyl twice a day by
nasogastric (NG) tube.
Case 1
A 75-year-old man with a past medical history of hyperlipidemia, hypertension, diabetes mellitus type 2 requiring insulin, obesity, and benign prostatic hyperplasia was admitted
to the hospital for a perirectal abscess. During admission, he
was tested and discovered to be positive for COVID-19, and
he confirmed subjective fever, altered mental status (memory loss and difficulty thinking), and hypoxia with chest tightness. A chest X-ray demonstrated a focal right basal infiltrate
suggestive of COVID-19 pneumonia (Figure 1). He was taken
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A

B

Figure 1. Chest X-ray findings upon admission (A) and upon leaving the intensive care unit (B) for patient in case 1.
Table 1. Inpatient laboratory results (case 1).
Day 1

Day 2

Day 3

Day 4

Glucose

155

142

98

89

Creatinine

1.43

1.53

1.32

1.14

1.6

0.5

0.6

0.3

23.5

13.6

Bilirubin total
CRP

numbers improved to 1.14 and 13.6, respectively (Table 1,
Figure 2). Additionally, he was no longer febrile, tachycardic,
tachypneic, or hypoxic. He left the ICU after 2.5 days of treatment with icosapent ethyl and antibiotics.
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Figure 2. Case #1: Inpatient labs.

to the operating room for drainage 24 h after admission to the
hospital, and that evening he was started on icosapent ethyl 2
g twice a day by NG tube. After the procedure, he was transferred to the ICU for hypoxia and continued systemic inflammatory response syndrome criteria. Two days later, he stated
that his symptoms had totally subsided except for pain near
the surgical site. Remarkably, his laboratory results reflected this improvement. Before treatment with icosapent ethyl,
his creatinine was 1.43 and CRP was 23.5. After 2 days, these
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On July 2. 2020, a 23-year old man with a past medical history
of obesity and diabetes presented to the ICU with acute kidney
injury (AKI), hypoxia, hypercapnia, respiratory failure secondary
to COVID-19, and on noninvasive positive-pressure ventilation
with bilevel positive airway pressure (BiPAP) with fraction of
inspired oxygen of 100% because of acute respiratory distress
syndrome (ARDS) along with obesity and hypoventilation that
exacerbated COVID-19-induced hypoxia. Upon admission, the
patient had a creatinine of 3.06. Aspartate aminotransferases
(AST) and alanine aminotransferases (ALT) were also elevated
at 949 U/L and 1208 U/L, respectively. On July 3 and 4, the patient was treated with tocilizumab, remdesivir, epoprostenol,
and convalescent plasma. Acute-phase reactants began trending down on July 4. The patient was weaned off epoprostenol
therapy on July 7, whereas he was transitioned to high-flow
nasal cannula during daytime with BiPAP at night because of
severe morbid obesity. Icosapent ethyl 2 g twice a day by NG
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Figure 3. Chest X-ray findings upon admission (A) and upon leaving the intensive care unit (B) for patient in case 2.
Table 2. Inpatient laboratory results (case 2).
7/3

7/4

7/5

7/6

7/7

7/8

7/9

Creatinine

1.36

1.11

1.07

ALT

949

668

418

296

216

170

122

AST

1208

338

107

77

40

28

LD

1784

957

832

769

635

565

Ferritin

896

596

421

376

336

CRP

23.1

9.1

4.1

2.1

1.1

0.94

tube was also started on this day. The patient began weaning off the high-flow nasal cannula on July 8. The chest X-ray
continued to show severe bilateral effusions and infiltrates
consistent with ARDS (Figure 3), but because of suspect fluid
overload, the patient was continued on Lasix for diuresis with
tracking of fluid intake and urine output. The patient completed
broad-spectrum antibiotics on July 9; the nephrologist signed
off for the patient’s AKI on July 9, whereas the infectious disease specialist signed off on July 10. At the time of nephrologist sign-off, the patient had a creatinine of 0.78. AST and ALT
were also at 18 U/L and 122 U/L, respectively. The patient presented to the hospital with AKI, presumably due to COVID-19.
The work-up was minimal so the actual cause of AKI, given
its rapid resolution, is not clear. Bilateral lower-extremity duplex scan was negative for deep vein thrombosis (DVT), decreasing suspicion for pulmonary embolism or venous thromboembolism. The patient was continued on high-intensity DVT
prophylaxis with supportive care, a steroid course (solumedrol), and probiotics because of frequent bowel movements.
By July 10, chest X-rays began improving, acute-phase reactants were near baseline (Table 2, Figure 4), and supportive
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Figure 4. Case #2: Inpatient labs.

care was continued. Provided these laboratory results, worsening viral load was not suspected and ARDS was suspected in
the setting of COVID-19 pneumonia. The patient continued to
do well on BiPAP HS and Vapotherm/high-flow nasal cannula
during the day and displayed good diuresis. The patient was
also having issues with hyperglycemia and had been meeting
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Table 3. Inpatient laboratory results (case 3).
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7/16
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7/18

7/20

7/21

7/22

7/23

7/24

7/25

7/26

7/29

981

1397

1322

762

580

372

388

380

522

345

290

286

487

377

245

205

13.6

6.2

3.0

1.6

3.3

4.8
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6.5

18.1
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Figure 5. Case #3: Inpatient labs.

with the diabetes team. The patient was removed from the ICU
on July 14 and discharged on July 24 after 22 days.
Case 3
A 24-year old man with a past medical history of autism contracted COVID-19 at his group home, and diagnosis of infection was confirmed by PCR. Subsequently, he was admitted
to the ICU and intubated for respiratory distress. He developed ARDS in the setting of COVID-19 pneumonia on July 10.
The patient was treated with tocilizumab, remdesivir, epoprostenol, dexamethasone, and convalescent plasma. Icosapent
ethyl was given from July 11 to July 14, mistakenly discontinued from July 15 to July 19, and subsequently restarted on July
20 after he developed severe pulmonary inflammation secondary to COVID-19. Of interest, when this patient was taking icosapent ethyl as an adjunct, inflammatory markers and
acute-phase reactants trended toward near baseline only after
3 days of administration (Table 3, Figure 5). During the time in
which this patient was not taking icosapent ethyl, his inflammatory markers increased in conjunction with his ventilatory
requirement and he required significant supportive measures.
In addition to broad-spectrum antibiotics, icosapent ethyl appeared to be responsible for his improvement from septic
shock, and once again, acute-phase reactants and ventilatory requirements were significantly decreased in just 3.5 days.
He was discharged to rehabilitation on August 7.
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Discussion
In this clinical presentation, we have described 3 cases; in 1, a
75-year-old patient presented for an abscess but soon developed ARDS secondary to COVID-19. Two days after administration of icosapent ethyl, inflammatory markers improved, and
he was moved from the ICU. In the second case, a 23-year-old
man presented with ARDS and respiratory failure also due to
COVID-19. Inflammatory markers began trending down after
administration of antiviral therapy, immunosuppressive therapy, and convalescent plasma but the patient was still being
considered for intubation before administration of icosapent
ethyl. However, 3 days after the addition of icosapent ethyl
as an adjuvant, the patient’s chest X-ray resolved, and acutephase reactants declined to near baseline levels. In the third
case, a 24-year-old man was intubated for ARDS secondary
to COVID-19. His case is notable in that he only demonstrated improvement while taking icosapent ethyl.
Icosapent ethyl, as previously stated, is indicated for the treatment of persistent hypertriglyceridemia and has also been
shown to reduce the risk of major coronary events [7]. The reduction in such events has been shown to occur with only a
marginal reduction in triglyceride levels, as seen in the Japan
EPA Lipid Intervention Study and the icosapent ethyl REDUCEIT trial, suggesting that the therapeutic effects may be related to its anti-inflammatory mechanisms [17]. Indeed, a significant reduction in inflammatory markers with icosapent ethyl
has been shown in the ANCHOR and MARINE trials with applications to a variety of other diseases including metabolic syndrome [11] and chronic kidney disease (CKD) [18]. Specifically,
studies have shown that icosapent ethyl significantly lowers
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levels of, among other markers, hsCRP levels compared with
placebo [11,12]. With COVID-19, prominent causes of mortality,
including pneumonia and ARDS, have been shown to be associated with elevated inflammatory markers including CRP, ILs,
granulocyte colony-stimulating factors, interferons, and TNFs
that cause pulmonary inflammation and lung damage [5,19].
As serum levels of cytokines have been shown to directly correlate with severity of the infection in COVID-19 patients, pharmacotherapy such as dexamethasone, corticosteroids, and IL
antagonists such as tocilizumab have shown therapeutic effect in COVID-19 treatment [20], supporting the possibility of
using icosapent ethyl as another potential form of treatment.
We presented 3 patients infected with SARS-CoV-2 who developed hypoxia with infiltrates on imaging, suggestive of ARDS
secondary to COVID-19 pneumonia [21]. With icosapent ethyl
and antibiotics alone, the 75-year-old patient improved remarkably, quantitively assessed by a reduction in his creatinine and
CRP, with resolution of his tachycardia, tachypnea, and hypoxia. The 23-year-old benefitted initially with an immunosuppressive and antiviral regimen, followed by complete resolution of
his chest X-ray and acute-phase reactants near baseline just 3
days after addition of icosapent ethyl. The 24-year-old showed
improvement primarily while taking icosapent ethyl as an adjunct during his ICU stay. These findings were reflected in their
laboratory results, suggesting the role of inflammation in the immunopathology of COVID-19 pulmonary disease and treatment.
In addition to these findings, a more recently published 2-case
series involving a 53-year-old woman and her 21-year-old
healthy daughter showed some similar beneficial effects of icosapent ethyl in reducing symptoms in COVID-19 patients [15].
Both the mother and the daughter had similar genetic and

medical backgrounds and only differed in age. After exposure
to SARS-CoV-2 and the development of similar symptoms, both
were treated with similar symptomatic care, but only the mother received icosapent ethyl. Although the mother’s symptoms
resolved by symptom day (SD) 7, the daughter’s symptoms resolved only on SD18 [15]. This case series demonstrated the
relative reduced duration of symptoms when icosapent ethyl
was added to a treatment regimen, speaking to its anti-inflammatory capabilities, specifically with COVID-19 patients. With
regard to our own cases, it is important to note that cases 2
and 3 demonstrated more severe COVID-19 pneumonia with
more extensive supportive treatments compared with those
of case 1. Thus, although the actual effect of IPE is more unclear and difficult to interpret in these contexts, the correlation between time of initiation of icosapent ethyl and rapid
clinical improvement can be appreciated in all 3 cases. Similar
to what was seen in the recent 2-case series, rapid improvement of symptoms after icosapent ethyl administration demonstrates its likely immunomodulatory effects and the immunopathogenesis of COVID-19.

Conclusions
This report of 3 cases describes the use of icosapent ethyl as
a component of supportive treatments in ICU patients with
moderate to severe COVID-19 pneumonia. However, as of yet
there are no evidence-based treatments for SARS-CoV-2 infection from controlled clinical trials. The outcomes of ongoing
clinical trials are awaited to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2
infection and which patients might benefit from the use of
this adjunctive treatment.
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